ReviewMetabolic brain disease2026
α-Klotho as a central integrative signalling hub in cognitive function and neuroprotection in neurodegenerative diseases.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
α-Klotho, a transmembrane protein predominantly expressed in the kidney and brain, has garnered significant attention for its anti-ageing and neuroprotective properties. Beyond its systemic role in mineral metabolism and oxidative stress regulation, emerging evidence highlights its critical involvement in maintaining cognitive function and protecting against neurodegenerative processes. This review explores the multifaceted role of α-Klotho in the central nervous system, emphasizing its physiological functions, underlying molecular mechanisms, and therapeutic potential. α-Klotho exerts neuroprotective effects by modulating calcium and phosphate homeostasis, attenuating oxidative stress, and suppressing neuroinflammation. Additionally, it regulates signalling pathways such as IGF-1, Wnt/β-catenin, and Nrf2, which are essential for neuronal survival and synaptic plasticity. Reduced α-Klotho expression has been linked to cognitive impairment, Alzheimer's disease, Parkinson's disease, and other age-related neurodegenerative disorders. Preclinical studies demonstrate that enhancing α-Klotho expression or administering a recombinant protein improves learning, memory, and neuronal resilience, positioning α-Klotho as a promising therapeutic target. However, challenges such as limited blood-brain barrier penetration, stability of recombinant forms, and incomplete mechanistic understanding hinder clinical translation. Overall, α-Klotho stands as a novel biomarker and a promising intervention strategy for mitigating neurodegeneration and promoting healthy brain ageing.
Indexed as
Identifiers
42274849What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.